Interview: Éric Gervais, Executive Vice President, Médunik Canada
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Médunik Canada is dedicated to developing strong partnerships with non-Canadian pharmaceutical and biopharmaceutical companies that are attempting to optimize the return on investment of their orphan drugs; they need to balance the financial risks and complexities associated to the introduction and distribution of their products on the small-size Canadian market. Through in-licensing partnerships, Médunik Canada offers turn-key operations – ranging from regulatory approval strategy to post-approval activities – to assure the commercial success of the partners’ product development efforts.
Medunik Canada
950, boul. Michèle-Bohec
Blainville (Québec) Canada
J7C 5E2
Tel.: + 1 450 433-4441
Fax: + 1 450 433-2211
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Jan Hux is the President and CEO of Diabetes Canada. Canadians have been at the forefront of tackling diabetes since the discovery of insulin. Now that the disease has become…
Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments. As a Canadian who…
John Fowler founded 7ACRES, a licensed producer of cannabis, in 2013. In 2014, 7ACRES went over to become part of The Supreme Cannabis Company, which today stands as a unique…
Mark Ware, the Chief Medical Officer of Canopy Growth Corporation, has intensely investigated the effects of cannabinoids, making him perfectly placed to cover this new era of cannabis in healthcare. …
Canadian medical cannabis company Tilray’s stock surged by over 77 percent in the first three trading days of last week before dropping dramatically by 47.9 percent to close out the…
Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMMS) for PharmaBoardroom. Today more Canadians are dying in this crisis than at the height of…
As cannabis in Canada cruises towards legalization, Pharma giants race for patented products. Big Pharma is establishing a significant cannabis presence in Canada with registered patents in advance of…
While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma –…
Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson.…
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
See our Cookie Privacy Policy Here